bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Significant Growth in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 239,800 shares, an increase of 107.6% from the February 28th total of 115,500 shares. Currently, 2.6% of the shares of the stock are sold short. Based on an average daily volume of 261,100 shares, the days-to-cover ratio is currently 0.9 days.

Institutional Investors Weigh In On bioAffinity Technologies

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC increased its position in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,304 shares of the company’s stock after buying an additional 26,304 shares during the quarter. Sheaff Brock Investment Advisors LLC owned 0.30% of bioAffinity Technologies worth $42,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Price Performance

Shares of BIAF traded down $0.01 during trading hours on Friday, reaching $0.26. 89,489 shares of the company’s stock traded hands, compared to its average volume of 161,875. bioAffinity Technologies has a 12 month low of $0.25 and a 12 month high of $3.16. The company has a current ratio of 1.02, a quick ratio of 1.01 and a debt-to-equity ratio of 0.18. The stock has a market cap of $4.08 million, a PE ratio of -0.32 and a beta of 3.12. The firm’s 50 day simple moving average is $0.57 and its 200-day simple moving average is $1.08.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.